OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

HTML

Year: 2007
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Neuropsychopharmacology
DOI: 10.1038/sj.npp.1301531
Authors: Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson
Institutions: Orexigen Therapeutics (United States), Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English

Topic: Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Subfield: Experimental and Cognitive Psychology
Field: Psychology
Domain: Social Sciences
Keywords: generalized anxiety disorder, LY354740, prodrugs, anxiety treatment, drug efficacy, tolerability, adverse events, convulsions
SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, Orexigen Therapeutics
OpenAlex ID: W2009617328
FWCI: 10.72
Cites: 38
Cited by: 191
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms